Cardiol Therapeutics Inc (CRDL)

06:20 AM

Cardiol Therapeutics Inc. (NASDAQ:CRDL) Receives $8.40 Average PT from Analysts - Defense World

06:20 AM

02:50 AM

Cardiol Therapeutics (NASDAQ:CRDL) Receives Buy Rating from HC Wainwright - Defense World

02:50 AM

Feb 22, 2025

Cardiol Therapeutics Inc. - MENAFN.COM

Feb 22, 2025

Feb 21, 2025

JACC data highlights Cardiol’s potential to differentiate in HF space - Yahoo Finance

Feb 21, 2025

Feb 20, 2025

Cardiol Therapeutics reports heart failure treatment progress By Investing.com - Investing.com Nigeria

Feb 20, 2025

Feb 20, 2025

Cardiol Therapeutics says study shows benefit of cannabidiol drug in treating heart failure - Proactive financial news

Feb 20, 2025

Feb 20, 2025

Cardiol Therapeutics reports heart failure treatment progress - Investing.com India

Feb 20, 2025

Feb 20, 2025

Cardiol Therapeutics Advances Heart Failure Treatment with New Research Publication - TipRanks

Feb 20, 2025

Feb 20, 2025

Revolutionary Heart Failure Treatment Shows Promise: Top Medical Journal Validates Multiple Therapeutic Benefits - StockTitan

Feb 20, 2025

Feb 19, 2025

Cardiol Therapeutics: Bargain Stock Price With Share Price Appreciation Catalysts (NASDAQ:CRDL) - Seeking Alpha

Feb 19, 2025

Feb 15, 2025

Cardiol Therapeutics (TSE:CRDL) Hits New 52-Week LowHere's Why - MarketBeat

Feb 15, 2025

Feb 13, 2025

Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx(TM) for Treatment of Acute Myocarditis - Newsfile

Feb 13, 2025

Feb 13, 2025

Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot - Newsfile

Feb 13, 2025

Feb 13, 2025

Biogen (NASDAQ:BIIB) vs. Cardiol Therapeutics (NASDAQ:CRDL) Head to Head Contrast - Defense World

Feb 13, 2025

Feb 11, 2025

Cardiol Therapeutics (TSE:CRDL) Shares Down 7.7%What's Next? - MarketBeat

Feb 11, 2025

Feb 08, 2025

Cardiol Therapeutics (TSE:CRDL) Trading Down 7.7% – Time to Sell? - Defense World

Feb 08, 2025

Feb 07, 2025

Cardiol Therapeutics (OTCMKTS:CRTPF) Trading 5.3% Higher – Here’s Why - Armenian Reporter

Feb 07, 2025

Feb 06, 2025

Cardiol Therapeutics (OTCMKTS:CRTPF) Stock Price Up 5.3% – Time to Buy? - Defense World

Feb 06, 2025

Feb 04, 2025

Cardiol Therapeutics to present at Oppenheimer Healthcare Conference - Proactive Investors UK

Feb 04, 2025

Feb 04, 2025

Cardiol Therapeutics to Present at Healthcare Conference, Highlighting Advances in Heart Disease Therapies - TipRanks

Feb 04, 2025

Feb 04, 2025

Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Newsfile

Feb 04, 2025

Feb 04, 2025

Heart Disease Breakthrough: Cardiol Therapeutics Unveils Latest Research at Major Healthcare Summit - StockTitan

Feb 04, 2025

Feb 03, 2025

Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol - Yahoo Finance

Feb 03, 2025

Feb 02, 2025

Cardiol Therapeutics (NASDAQ:CRDL) Rating Increased to Strong-Buy at RODMAN&RENSHAW - MarketBeat

Feb 02, 2025

Feb 01, 2025

Analysts Set Cardiol Therapeutics Inc. (NASDAQ:CRDL) PT at $8.40 - MarketBeat

Feb 01, 2025

Feb 01, 2025

Reviewing Cardiol Therapeutics (NASDAQ:CRDL) and CG Oncology (NASDAQ:CGON) - Defense World

Feb 01, 2025

Jan 31, 2025

Cardiol Therapeutics (NASDAQ:CRDL) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat

Jan 31, 2025

Jan 31, 2025

Brokerages Set Cardiol Therapeutics Inc. (NASDAQ:CRDL) Price Target at $8.40 - Defense World

Jan 31, 2025

Jan 30, 2025

Cardiol Therapeutics (NASDAQ:CRDL) Raised to Strong-Buy at RODMAN&RENSHAW - Defense World

Jan 30, 2025

Jan 30, 2025

Rodman & Renshaw Begins Coverage on Cardiol Therapeutics (NASDAQ:CRDL) - Defense World

Jan 30, 2025

Jan 28, 2025

Rodman & Renshaw sets $7 target on Cardiol Therapeutics stock - MSN

Jan 28, 2025

Jan 28, 2025

Rodman & Renshaw sets $7 target on Cardiol Therapeutics stock By Investing.com - Investing.com Canada

Jan 28, 2025

Jan 17, 2025

Cardiol Therapeutics (TSE:CRDL) Trading Down 3.4%What's Next? - MarketBeat

Jan 17, 2025

Jan 17, 2025

Jane Street Group LLC Takes $29,000 Position in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World

Jan 17, 2025

Jan 17, 2025

Cardiol Therapeutics (TSE:CRDL) Shares Down 3.4% – Here’s What Happened - Defense World

Jan 17, 2025

Jan 15, 2025

Critical Comparison: Black Diamond Therapeutics (NASDAQ:BDTX) & Cardiol Therapeutics (NASDAQ:CRDL) - Defense World

Jan 15, 2025

Jan 15, 2025

Pericarditis Drugs Market reached US$ 544.4 million in 2023 - openPR

Jan 15, 2025

Jan 14, 2025

Top 4 Canadian Biotech Stocks (Updated January 2025) - Investing News Network

Jan 14, 2025

Jan 01, 2025

Cardiol Therapeutics Inc. (NASDAQ:CRDL) Short Interest Up 12.4% in December - MarketBeat

Jan 01, 2025

Dec 31, 2024

Appendix 3Y x4 - Investing News Network

Dec 31, 2024

Dec 27, 2024

Cardiol Therapeutics Sees Insider Buying From Leadership Team And Board Members - The Deep Dive

Dec 27, 2024

Dec 26, 2024

Guillermo Torre Purchases 17,240 Shares of Cardiol Therapeutics Inc. (TSE:CRDL) Stock - MarketBeat

Dec 26, 2024

Dec 24, 2024

Insider Buying: Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Buys 18,900 Shares of Stock - MarketBeat

Dec 24, 2024

Dec 24, 2024

2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases - Proactive Investors Australia

Dec 24, 2024

Dec 23, 2024

2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases | NASDAQ:CADL - Proactive Investors UK

Dec 23, 2024

Dec 21, 2024

HC Wainwright Has Positive Forecast for CRDL FY2024 Earnings - Defense World

Dec 21, 2024

Dec 20, 2024

FY2024 Earnings Forecast for CRDL Issued By HC Wainwright - MarketBeat

Dec 20, 2024

Dec 19, 2024

RAD 202 receives approval to start Phase 1 therapeutic trial - Investing News Network

Dec 19, 2024